TOMI Environmental Solutions Announces Specialized Service Provider for Healthcare and Mold Remediation
TOMI Environmental Solutions (NASDAQ:TOMZ), a global decontamination and infection prevention company, has secured a new service provider who invested $185,500 in SteraMist mobile systems and BIT solution. The provider will focus on mold and mycotoxins remediation in healthcare, having already secured a contract to remediate a 400,000-cubic-feet hospital space including HVAC decontamination.
The company also highlighted its ongoing partnership with Enviro-Mist Inc., which maintains a multi-year service contract with Pfizer and continues to use SteraMist technology for mold remediation and decontamination in pharmaceutical facilities across the West Coast.
TOMI Environmental Solutions (NASDAQ:TOMZ), una società globale di decontaminazione e prevenzione delle infezioni, ha assicurato un nuovo fornitore di servizi che ha investito $185,500 in sistemi mobili SteraMist e nella soluzione BIT. Il fornitore si concentrerà sulla bonifica di muffe e micotossine negli ambienti sanitari, avendo già ottenuto un contratto per bonificare uno spazio ospedaliero di 400.000 piedi cubi, inclusa la decontaminazione HVAC.
L'azienda ha inoltre evidenziato la sua continua partnership con Enviro-Mist Inc., che mantiene un contratto di servizio pluriennale con Pfizer e continua a utilizzare la tecnologia SteraMist per la bonifica e la decontaminazione di muffe in impianti farmaceutici lungo la costa ovest.
TOMI Environmental Solutions (NASDAQ:TOMZ), una empresa global de descontaminación y prevención de infecciones, ha asegurado un nuevo proveedor de servicios que invirtió $185,500 en sistemas móviles SteraMist y en la solución BIT. El proveedor se centrará en la remediación de moho y micotoxinas en entornos sanitarios, y ya ha obtenido un contrato para remediar un espacio hospitalario de 400,000 pies cúbicos, incluida la descontaminación HVAC.
La empresa también destacó su asociación en curso con Enviro-Mist Inc., que mantiene un contrato de servicio plurianual con Pfizer y continúa utilizando la tecnología SteraMist para la remediación y descontaminación de moho en instalaciones farmacéuticas a lo largo de la Costa Oeste.
TOMI Environmental Solutions (NASDAQ:TOMZ)는 전 세계적인 오염 제거 및 감염 예방 기업으로, 새로운 서비스 제공업체가 $185,500를 투자한 SteraMist 모바일 시스템 및 BIT 솔루션에 투자했습니다. 공급자는 의료기관의 곰팡이 및 마이코톡신 제거에 집중할 예정이며 HVAC 제균을 포함한 400,000입방피트의 병원 공간 제거 계약을 이미 확보했습니다.
또한 이 회사는 Pfizer와 다년간의 서비스 계약을 유지하고 서해안의 제약 시설에서 곰팡이 제거 및 제균에 SteraMist 기술을 지속적으로 활용하는 Enviro-Mist Inc.와의 지속적인 파트너십을 강조했습니다.
TOMI Environmental Solutions (NASDAQ:TOMZ), une société mondiale de décontamination et de prévention des infections, a sécurisé un nouveau prestataire qui a investi $185,500 dans des systèmes mobiles SteraMist et la solution BIT. Le prestataire se concentrera sur l’assainissement des moisissures et des mycotoxines dans les établissements de santé, ayant déjà obtenu un contrat pour réhabiliter un espace hospitalier de 400 000 pieds cubes, y compris la décontamination HVAC.
La société a également souligné son partenariat continu avec Enviro-Mist Inc., qui maintient un contrat de service pluriannuel avec Pfizer et continue d’utiliser la technologie SteraMist pour l’assainissement et la décontamination contre les moisissures dans les installations pharmaceutiques le long de la côte ouest.
TOMI Environmental Solutions (NASDAQ:TOMZ), ein globales Unternehmen für Desinfektion und Infektionsprävention, hat einen neuen Dienstleister gewonnen, der $185,500 in mobile SteraMist-Systeme und die BIT-Lösung investiert hat. Der Anbieter wird sich auf die Sanierung von Schimmel und Mykotoxinen im Gesundheitswesen konzentrieren und hat bereits einen Vertrag zur Sanierung eines 400.000 Kubikfuß großen Krankenhausbereichs inklusive HVAC-Entkeimung gesichert.
Das Unternehmen hob auch seine laufende Partnerschaft mit Enviro-Mist Inc. hervor, die einen mehrjährigen Servicevertrag mit Pfizer unterhält und weiterhin SteraMist-Technologie für SchimmelSanierung und Entkeimung in pharmazeutischen Einrichtungen an der West Küste einsetzt.
TOMI Environmental Solutions (NASDAQ:TOMZ)، شركة عالمية للتطهير والوقاية من العدوى، قد أمنت مزود خدمة جديد استثمر $185,500 في أنظمة SteraMist المتنقلة وحل BIT. سيتركّز المزود على إصلاح العفن وميكوتوكسينات في الرعاية الصحية، وقد أبرم عقداً لإصلاح مساحة مستشفى سعتها 400,000 قدم مكعب بما في ذلك تعطيل HVAC.
كما أبرزت الشركة شراكتها المستمرة مع Enviro-Mist Inc.، التي تحافظ على عقد خدمة لعدة سنوات مع Pfizer وتواصل استخدام تقنية SteraMist لإصلاح العفن والتطهير في مرافق الأدوية على الساحل الغربي.
TOMI Environmental Solutions (NASDAQ:TOMZ),一家全球性消毒与感染防护公司,已确定了一家新服务提供商,该公司在 SteraMist 移动系统和 BIT 解决方案上投资了 $185,500。该提供商将专注于医疗机构的霉菌及霉菌毒素治理,已获得一份合同,需治理一个体积为 400,000 立方英尺 的医院空间,其中包括 HVAC 的消毒。
公司还强调了与 Enviro-Mist Inc. 的持续合作关系,Enviro-Mist 与辉瑞(Pfizer)维持多年的服务合同,并继续在西海岸的药品制造设施中使用 SteraMist 技术进行霉菌治理和消毒。
- New service provider made significant investment of $185,500 in SteraMist systems
- Provider secured major 400,000-cubic-feet hospital remediation contract
- Ongoing multi-year service contract with Pfizer facility through partner Enviro-Mist
- Heavy reliance on single or few products for majority of revenues
- Business growth dependent on service provider performance
Insights
TOMI secured a new healthcare service provider generating $185,500 in equipment sales and expanding its disinfection technology's market reach.
TOMI has secured a noteworthy new service provider that has made a
The strategic significance extends beyond immediate revenue. By partnering with operators who have existing industry relationships and technical expertise in restoration, TOMI is effectively expanding its market presence without incurring direct sales costs. The connection to Enviro-Mist, which maintains a multi-year Pfizer contract, creates a network effect that enhances credibility in pharmaceutical and healthcare applications - sectors with stringent disinfection requirements and higher margins.
TOMI's technology differentiation stems from its DARPA-originated Binary Ionization Technology using ionized hydrogen peroxide (iHP), which offers advantages over conventional disinfection methods. The company is executing a classic razor/razor blade business model, where initial equipment sales (
FREDERICK, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a new service provider this quarter, expanding the use of its SteraMist iHP technology. This new provider has invested approximately
"We are incredibly excited to partner with them as they make strides into the healthcare industry," said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. "Their leadership, which includes a prominent figure in restoration and seasoned personnel, brings unique industry and operating expertise. They have been extensively trained on our technology and are well-prepared to deliver exceptional service."
This new service provider also has a working relationship with Enviro-Mist Inc., a long-standing exclusive partner of TOMI and experts in mold remediation. Enviro-Mist Inc. continues to use SteraMist for mold remediation as well as the decontamination of pharmaceutical and life sciences facilities throughout the West Coast, including a multi-year service contract for a Pfizer facility.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products to serve healthcare sectors. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
tomi@imsinvestorrelations.com